undamentalytics Newsletter
Sign in

Cullinan Therapeutics, Inc. (CGEM) stock

Add to watchlist

Add holding +

NASDAQ: CGEM Nasdaq Biotechnology Next results ~November 14, 2026

Cullinan Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 5 selling0 purchases and 28 sales by directors and officers, last 12 monthsInsider trades
  • Funds111 adding, 67 cuttingOf 44 active managers that changed their stake, 24 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 14, 2026 (estimated)

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Revenue shrinking. Revenue fell 100.0% over the last 12 months.
  • Loss-making. Operating margin is -358.7%: costs exceed revenue.
  • Heavy stock-based pay. Stock pay equals 128.7% of revenue: a real cost that cash-flow figures leave out.
  • Share dilution. Diluted shares rose 14.8% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 78% and a beta of 1.6 against the S&P 500.
  • Heavily shorted. 16.5% of the shares available to trade are sold short (6.2 days of average volume to cover).

Latest results: FY2022 Q4

Filed March 9, 2023
Earnings per share
-$0.81 against an average estimate of -$0.85: beat by 4.8%
Share reaction
+0.7% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 14, 2026; average EPS estimate -$0.84

Cullinan Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.7%
  • 1 week+2.7%
  • 1 month-3.7%
  • This year+44.3%
  • 1 year+72.4%
  • 5 years-34.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 6, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Announcement
  4. Announcement
  5. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Cullinan Therapeutics, Inc. valuation models and calculator

No model value for Cullinan Therapeutics, Inc. at the moment. Current status: data-quality checks not passed. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 14, 2026, after the close. Analysts expect revenue of $0 and EPS of −$0.84 (range −$1.04 to −$0.71) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$3.13 +7% $14m 0%
Next −$2.47 +21% $56m +300%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +4.3% on 90 days ago. In the last 30 days, 3 analysts raised Cullinan Therapeutics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Cullinan Therapeutics, Inc., last 90 days
−$4.00 −$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$3.00 Current fiscal year, 60 days ago: −$3.17 Current fiscal year, 30 days ago: −$3.14 Current fiscal year, 7 days ago: −$3.13 Current fiscal year, Now: −$3.13 −$3.13 Next fiscal year, 90 days ago: −$2.53 Next fiscal year, 60 days ago: −$2.71 Next fiscal year, 30 days ago: −$2.75 Next fiscal year, 7 days ago: −$2.52 Next fiscal year, Now: −$2.47 −$2.47

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$3.00−$2.53
60 days ago −$3.17−$2.71
30 days ago −$3.14−$2.75
7 days ago −$3.13−$2.52
Now −$3.13−$2.47

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.85 −$0.81 +4.8%
Mar 2026 −$0.84 −$0.75 +11.1%
Dec 2025 −$0.84 −$0.77 +8.2%
Sept 2025 −$0.89 −$0.77 +13.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

12 analysts, Oct 2026
Buy12100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202611112
  2. Sep 202611112
  3. Aug 202611112
  4. Jul 202611112

Counts of recommendations published by analysts covering Cullinan Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
16.5%
of tradable shares
Days to cover
6.17
at average volume
Short interest, 1 month
−21%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
0.4%
of shares
Employees
109
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20222023202420252026 to date
Return
CGEM−32%−3%+20%−15%+44%
Industry peers (median)−57%−18%−29%−5%−27%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
CGEM42%42%42%42%46%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
CGEM−56%−41%−63%−55%−44%
S&P 500−25%−10%−8%−19%−9%

Worst fall since January 8, 2021: 89% from March 10, 2021 to October 2, 2025. Getting back needed a 829% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$7.19 – $22.95
From 52-week high
−34.9%
vs 50-day average
−16.0%
vs 200-day average
−5.7%
Volatility (1 year)
79%
Beta vs S&P 500
1.59

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 9 down
typical move ±3.5%
After a week
5 up, 7 down
typical move ±6.9%
After a month
5 up, 7 down
typical move ±17.7%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +0.7% +0.5% +11.5% +25.4%
May 7, 2026 −2.9% +0.5% +7.7% −11.4%
March 10, 2026 −6.5% −0.3% −12.2% −0.7%
January 8, 2026 −0.4% +0.7% −2.6% +8.1%
November 6, 2025 −1.6% −1.0% +13.1% +70.2%
August 7, 2025 −7.4% +0.7% −3.8% −13.2%
May 8, 2025 −2.1% +0.6% −6.0% +13.8%
February 27, 2025 +0.5% −0.1% +0.7% −5.1%
November 7, 2024 −2.8% +1.2% −7.2% −22.9%
August 8, 2024 +1.4% +2.8% +2.2% +10.3%
May 15, 2024 −9.7% +1.0% −12.3% −28.4%
March 14, 2024 −6.2% −0.9% −3.8% −2.5%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Cullinan Therapeutics, Inc.
$0 $5M $10M $15M $20M FY21 Q4 FY22 Q1 FY22 Q2 FY22 Q3 FY22 Q4 Revenue (TTM), FY21 Q4: $18.9M Revenue (TTM), FY22 Q1: $0 Revenue (TTM), FY22 Q2: $0 Revenue (TTM), FY22 Q3: $0 Revenue (TTM), FY22 Q4: $0 $0

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY21 Q4 $18.9M
FY22 Q1 $0
FY22 Q2 $0
FY22 Q3 $0
FY22 Q4 $0

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022
Income
Revenue 0 19 0
EBITDA −60 −68 145
Operating income −60 −68 145
Net income −52 −66 111
Diluted EPS −$2.60 −$1.52 $2.38
Growth (year on year)
Revenue — — −100.0%
Margins
EBITDA margin — −358.4% —
Operating margin — −358.7% —
Net margin — −346.1% —
Free-cash-flow margin — −229.3% —
Cash flow
Cash from operations −30 −43 −127
Capital spending 0 0 1
Free cash flow −30 −43 −128
Stock-based pay 15 24 28
Free cash flow after stock pay −45 −68 −156
Balance sheet
Cash 168 60 156
Total debt 0 0 0
Net debt (negative = net cash) −168 −60 −156
Diluted shares 20m 43m 47m
Returned to shareholders
Buybacks 7 — —
Total returned 7 — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Who owns it

Funds buying and selling
Reported value
$1.3B
Institutions reporting
183
Shares held vs prior quarter
▲ 9.4%
Positions opened / closed
29 / 20

Top buyers and sellers, Q2 2026: 111 institutions bought and 67 sold ; the biggest buyer was Mpm Bioimpact LLC (+2.1M shares) and the biggest seller Nextech Invest Ltd (−1.1M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Mpm Bioimpact LLC $177M 9.7M 13.6% ▲ 27.2%
Lynx1 Capital Management LP $163M 9.0M 12.5% 0.0%
Bvf Inc $105M 5.8M 8.0% 0.0%
Blackrock, Inc. $95.3M 5.2M 7.3% ▲ 17.6%
Price T Rowe Associates Inc $69.7M 3.8M 5.3% ▲ 88.5%
State Street Corp $66.8M 3.7M 5.1% ▲ 44.2%
Kynam Capital Management, LP $56.7M 3.1M 4.3% 0.0%
Vanguard Capital Management LLC $47.6M 2.6M 3.6% ▲ 5.3%
RTW Investments, LP $43.1M 2.4M 3.3% ▲ 38.6%
Siren, L.L.C. $34.5M 1.9M 2.6% ▲ 58.7%
Geode Capital Management, LLC $28.2M 1.5M 2.2% ▲ 13.1%
Blue Owl Capital Holdings LP $28M 1.5M 2.1% ▼ 19.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Cullinan Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $2.5M 28 trades by 5 insiders · 63% under pre-set plans
Net ▼ $2.5M net selling
Insider Date Trade Shares Price Value
Michaelson Jennifer Chief Scientific Officer September 8, 2026 Sell pre-set plan 8,000 $21.57 $172,560
Michaelson Jennifer Chief Scientific Officer August 13, 2026 Sell pre-set plan 30,000 $20.26 $607,800
Michaelson Jennifer Chief Scientific Officer July 6, 2026 Sell pre-set plan 8,000 $17.82 $142,560
Michaelson Jennifer Chief Scientific Officer May 5, 2026 Sell pre-set plan 7,800 $14.60 $113,880
Michaelson Jennifer Chief Scientific Officer May 5, 2026 Sell pre-set plan 200 $15.58 $3,116
Michaelson Jennifer Chief Scientific Officer March 5, 2026 Sell pre-set plan 8,000 $15.68 $125,440
Michaelson Jennifer Chief Scientific Officer February 25, 2026 Sell pre-set plan 1,780 $14.14 $25,169
Sumer Jacquelyn L Chief Legal Officer February 24, 2026 Sell 3,601 $14.47 $52,106
Jones Jeffrey Alan Chief Medical Officer February 24, 2026 Sell 4,582 $14.47 $66,302
Ahmed Nadim President and CEO February 24, 2026 Sell 13,515 $14.47 $195,562
Michaelson Jennifer Chief Scientific Officer February 24, 2026 Sell pre-set plan 3,601 $14.47 $52,106
Michaelson Jennifer Chief Scientific Officer February 23, 2026 Sell pre-set plan 1,752 $13.99 $24,510

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 26, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 7, 2026
  • March 10, 2026
  • January 8, 2026
  • November 6, 2025
  • August 7, 2025

Recent SEC filings

Data status

When each part of this page on Cullinan Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Cullinan Therapeutics, Inc. in brief

What does Cullinan Therapeutics, Inc. do?
Cullinan Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Cullinan Therapeutics, Inc.'s stock ticker?
Cullinan Therapeutics, Inc. trades under the ticker CGEM on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Cullinan Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Mpm Bioimpact LLC, Lynx1 Capital Management LP and Bvf Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Cullinan Therapeutics, Inc.'s market cap?
On December 30, 2022, Cullinan Therapeutics, Inc.'s market capitalisation was about $492M, with a price-to-earnings ratio of 4.4 and net debt of -$156M. Market figures come from third-party market data and may be delayed.
Are insiders buying or selling Cullinan Therapeutics, Inc. stock?
Over the last 12 months, Cullinan Therapeutics, Inc.'s directors and officers reported 0 open-market purchases and 28 sales on Form 4. The insider trading page charts every trade.
When is Cullinan Therapeutics, Inc.'s next earnings date?
Around November 14, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Cullinan Therapeutics, Inc. announces its own schedule.